肝硬化患者血浆前激肽释放酶的检测及其临床意义  

ASSAYANDCLINICALSIGNIFICANCEOFPLASMA PREKALLIKREININCIRRHOTICPATIENTS

作　　者：黄玉红[1] 傅宝玉[1] 刘金兰[1] 刘桂琴[1] 

机构地区：[1]中国医科大学第一医院消化内科

出　　处：《中华消化杂志》1995年第2期72-73,共2页Chinese Journal of Digestion

摘　　要：本文采用底物发色法测定６０例肝硬化患者、３０例健康人的血浆前激肽释放酶（ｐｒｅ－－Ｋａｌｌｉｋｒｅｉｎ，ＰＫ）水平。结果表明：肝硬化患者血浆ＰＫ水平显著降低，与肝功能损害程度有关，随肝功能损害程度的加重而降低。而且血清白蛋白（Ａ）水平及血浆凝血酶原时间（ＰＴ）正常的肝硬化患者血浆ＰＫ水平仍显著低于正常对照组。The plasma prekallikrein levels were measured in 60 patients with liver cirrhosis and 30normal controls using chromogenic substrate assay. Plasma prekallikrein levels weresignificantly decreased in patients with of liver cirrhosis and correlated to the degree of liverdamage. Moreover, they were also significantly decreased in cirrhotic patients with normalserum albumin level or plasma prothrombin time, as compared with normal controls. Theseresults suggest that plasma prekallikrein is a more sensitive index of liver damage than otherparameters.

关 键 词：激肽释放酶 激肽系统 肝硬变 检测 

分 类 号：R575.202[医药卫生—消化系统]